ACAD is pricing 8 million shares at $12.50 for a total of $100 million. The offering would bring their cash total to approximately $178 million at 2013 year's end company forecast. I like the move, as it can help in potential negotiations for partnership or outright purchase by a larger entity. The stock in pre-market is actually trading higher than the offering price which is extremely positive for now. The cash will also aid in running the Alzheimer's (ADP) trial phase II, and a European Parkinson's trial if they wish to. After the offering the share count will total around $88 million shares outstanding. We hold shares of ACAD. Thank you for reading.
No comments:
Post a Comment